Cyclosporine plasma unbound fraction in heart and lung transplantation recipients

Therapeutic Drug Monitoring

Volumn 21, Issue 1, 1999, Pages 8-16

  Akhlaghi, Fatemeh ^a,c   Ashley, John ^a   Keogh, Anne ^b   Brown, Kenneth ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

Cyclosporine; Heart transplantation; Lipoproteins; Organ rejection; Unbound fraction

Indexed keywords

AZATHIOPRINE; BILIRUBIN; CALCIUM; CARDIOVASCULAR AGENT; COLECALCIFEROL; COTRIMOXAZOLE; CYCLOSPORIN; DILTIAZEM; FLUCONAZOLE; GAMMA GLUTAMYLTRANSFERASE; ITRACONAZOLE; METHYLPREDNISOLONE; PRAVASTATIN; PREDNISOLONE; RANITIDINE; SIMVASTATIN;

ADOLESCENT; ADULT; AGE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BLOOD LEVEL; FEMALE; GRAFT REJECTION; HEART LUNG TRANSPLANTATION; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; CYCLOSPORINE; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIPIDS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; TIME FACTORS;

EID: 0033031148     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199902000-00003     Document Type: Article

References (35)

1. Niederberger W, Lemaire M, Maurer G, Nussbauer K, Wagner O. Distribution and binding of cyclosporine in blood and tissues. Transplant Proc 1983;15:2419-21.
2. Gurecki J, Warty V, Sanghvi A. The transport of cyclosporine in association with plasma lipoproteins in heart and liver transplant patients. Transplant Proc 1985;22:1997-2002.
3. Lindholm A, Henricsson S, Gang P. The free fraction of cyclosporine in plasma: Clinical findings with a new method. Transplant Proc 1988;20:377-81.
4. Akhlaghi F. Distribution of cyclosporine in plasma from heart transplant recipients. [doctoral thesis], University of Sydney, 1996.
5. Rowland M, Tozer TN. In: Clinical pharmacokinetics: Concepts and applications. 3rd ed. Philadelphia: Williams & Wilkins, 1995.
6. Rowland M. Protein binding and drug clearance. Clin Pharmacokinet 1984;9:10-17.
7. du Souich P, Verges J, Erill S. Plasma protein binding and pharmacological response. Clin Pharmacokinet 1993;24:435-40.
8. Levy RH, Moreland TA. Rationale for monitoring free drug levels. Clin Pharmacokinet 1984;9:1-9.
9. Lindholm A, Henricsson S. Intra- and interindividual variability in the free fraction of cyclosporine in plasma in recipients of renal transplant. Ther Drug Monit 1989;11:623-30.
10. Lindholm A. Monitoring of the free concentration of cyclosporine in plasma in man. Eur J Clin Pharmacol 1991;40:571-5.
11. Keogh A, Spratt P, McGosker C, Macdonald P, Mundy J, Kaan A. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 1995;333:628-33.
12. Morris RG, Tett SE, Ray JE. Cyclosporine A monitoring in Australia: Consensus recommendations. Ther Drug Monit 1994;16: 570-6.
13. Billingham ME, Gary NR, Hammond ME, Kemnitz J, Marhoe C, McCallister HA. A working formulation for the standardisation of nomenclature in the diagnosis of heart and lung rejection: Heart rejection study group. J Heart Transplant 1990;9:587-95.
14. Akhlaghi F, Mclachlan AJ, Keogh AM, Brown KF. Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients, Br J Clin Pharmacol. 1997;44:537-42.
15. Converse CA, Skiner ER, eds. Lipoprotein analysis: A practical approach. Oxford: Oxford University Press, 1992.
16. Walker R, Edward C, eds. Clinical pharmacy and therapeutics. New York: Churchill Livingstone, 1994.
17. Macdonald P, Keogh A, Connell J, Harvison A, Richens D, Spratt P. Diltiazem co-administration reduces cyclosporine toxicity after heart transplantation: A prospective randomised study. Transplant Proc 1992;24:2259-62.
18. Lindholm A. Cyclosporine A: Clinical experience and therapeutic drug monitoring. Ther Drug Monit 1995;17:631-7.
19. Fahr A. Cyclosporine clinical pharmacokinetics. Clin Pharmacokinet 1993;2:472-95.
20. Venkataramanan R, Ptachinski RJ, Burckart GJ, Yang S, Starzl TE. Extraction ratio of cyclosporine in a liver transplant patient with organ rejection. J Pharm Sci 1985;74:901-2.
21. Rowland M. Protein binding and drug clearance. Clin Pharmacokinet 1984;9:10-7.
22. deGroen PC. Cyclosporine, low-density lipoprotein, and cholesterol. Mayo Clin Proc 1988;63:1012-21.
23. Stulnig TM, Klocker H, Harwood HJ, et al. In vivo LDL receptor and HMG-CoA reductase regulation in human lymphocytes and its alterations during aging. Arterioscler Thromb Vasc Biol 1995;15: 872-8.
24. Yee GC, Lennon TP, Gmur DJ, Kennedy MS, Deeg HJ. Age-dependent cyclosporine pharmacokinetics in marrow transplant recipients. Clin Pharmacol Ther 1986;40:438-43.
25. Vaughan WJ, Lindgren FT, Whalen JB, Abraham S, Serum lipoprotein concentrations in cystic fibrosis. Science 1978;199:783-6.
26. Levey E, Roy C, Lacaille F, et al. Lipoprotein abnormalities associated with cholesteryl ester transfer in cystic fibrosis patients: The role of essential fatty acid deficency. Am J Clin Nutr 1993; 57:573-9.
27. Zini R, Riant P, Barre J, Tillemont JP. Disease induced variations in plasma protein levels: Implications for drug and protein regimens. Clin Pharmacokinet 1990;19:147-229.
28. McKenzie FN, Moses GC, Henderson AR. Routine 'cardiac' and 'hepatic' serum enzyme profiles in cardiac transplant patients treated with cyclosporine A: Operative and post operative findings. Clin Chem 1985;31:822-5.
29. Gulbis B, Adler M, Ooms HA, Desmet JM, Jeclerc JL, Primo G. Liver-function studies in heart transplant recipients treated with cyclosponne A. Clin Chem 1988;34:1772-4.
30. Wisecarver JL, Earl RA, Haven MC, Timmins PW, Shaw BW, Stratta RJ. Histologic changes in liver allograft biopsies associated with elevated whole blood and tissue cyclosporine concentrations. Mod Pathol 1992;5:611-6.
31. First MR, Schroeder TJ, Alexander JW, et al. Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. Transplantation 1991;2:365-70.
32. Butman SM, Wild JC, Nolan PE, et al. Prospective study of the safety and financial benefit of ketoconazole as adjunctive therapy to cyclosporine after heart transplantation. J Heart Lung Transplant 1991;10:351-8.
33. Pool PE, Seagren SC, Salel AF. Effects of diltiazem on serum lipids, exercise performance and blood pressure: Randomized, double-blind, placebo-controlled evaluation for systemic hypertension. Am J Cardiol 1985;56:86-91.
34. Gheissari A, Yokoyama T, Hendel J, Capouya E, Fuentes J, Jimenez P. Diltiazem prevents accelerated graft coronary artery disease in heart transplant recipients. Transplant Proc 1995;27:2625-7.
35. Akhlaghi F, Ashley JJ, Keogh AM, Brown KF. Indirect estimation of the unbound fraction of cyclosporine in plasma. Ther Drug Monit 1998;20:301-8.